Embark IPO
Embark is a canine genetics company that provides DNA testing services for dogs, helping pet owners understand their dogs' breed composition, health risks, and genetic traits. The company has built a significant database of canine genetic information and offers both consumer and veterinary products. Investors may be interested in Embark due to the growing pet care market and increasing consumer spending on pet health and wellness.
Key Facts
| Industry | Pet Genetics |
| Founded | 2015 |
| Headquarters | Boston, MA |
| Employees | ~200 |
| Website | embark.com |
| Funding | Series B raised $75M in 2021. Total raised: ~$100M |
About Embark
Embark Veterinary is the leading dog DNA testing company, offering comprehensive genetic testing services that screen for over 230 health conditions, 350+ breeds, and provide detailed ancestry information. The company has built the world's largest database of dog genetic information, with over one million dogs tested, enabling breakthrough research in canine genetics and health.
Founded by brothers Ryan and Adam Boyko, with Ryan being a former postdoc at Cornell's veterinary school, Embark combines consumer genetic testing with serious scientific research. The company partners with veterinarians, breeders, and researchers to advance understanding of canine genetics and develop new treatments for inherited diseases. Embark's platform provides actionable health insights that help dog owners and veterinarians make informed decisions about preventive care, breeding, and treatment options. The company has published numerous peer-reviewed research papers and contributed significantly to the scientific understanding of dog genetics.
IPO Status
Embark has not announced any plans to go public and remains a private company. The company has raised venture capital funding to expand its canine genetics testing services and build out its genetic database, but specific valuation details have not been publicly disclosed. There are currently no confirmed reports or rumors regarding Embark's IPO timeline. As a specialized player in the pet genetics market, the company would likely need to demonstrate significant scale and market penetration before considering a public offering. The broader pet care and diagnostics industry has seen some public market interest, which could potentially create opportunities for companies like Embark in the future.
Competitors
Frequently Asked Questions
Does Embark have a stock?
No, Embark has not had an IPO and remains a private company. The canine genetics testing company has not announced any plans to go public.
When is the Embark IPO date?
There is no confirmed IPO date for Embark, as the company has not announced plans to go public. No timeline or IPO preparations have been reported.
How can I buy Embark stock?
You cannot currently buy Embark stock as it is a private company that has not gone public. The stock is not available on public exchanges like NYSE or NASDAQ.
Stay Updated on the Embark IPO
Get real-time alerts when Embark files for an IPO, prices shares, or begins trading.
Get IPO Alerts